NAM
YARW

Nexpoint Asset Management’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Nexpoint Asset Management’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11
Closed -$69K – 196
2021
Q1 		$69K Hold
11
– – 0.02% 159
2020
Q4 		$64K Hold
11
– – 0.02% 141
2020
Q3 		$67K Hold
11
– – 0.02% 154
2020
Q2 		$70K Buy
11
+8
+267% +$54.2K 0.02% 184
2020
Q1 		$27K Buy
+3
New +$47.1K 0.01% 212

Other funds holding YARW

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Nexpoint Asset Management's YARW Position: Q2 2021 in Review

Nexpoint Asset Management sold out of Yarrow Bioscience, Inc. Common Stock (YARW) in Q2 2021, closing a stake of 11 shares — an estimated $69K sold.

Nexpoint Asset Management first reported a position in YARW in Q1 2020 and held it in 5 quarters. The position peaked at $70K in Q2 2020. 63 funds tracked by Wall St. Rank hold YARW as of Q2 2021.

  • Nexpoint Asset Management reported no remaining Yarrow Bioscience, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Nexpoint Asset Management sold 11 Yarrow Bioscience, Inc. Common Stock shares in Q2 2021, an estimated $69K.
  • Nexpoint Asset Management first reported a position in Yarrow Bioscience, Inc. Common Stock in Q1 2020 and held it in 5 quarters.
  • Nexpoint Asset Management's Yarrow Bioscience, Inc. Common Stock position peaked at $70K in Q2 2020.
  • 63 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q2 2021.

Based on Nexpoint Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.